Two Appointed to ONI’s Editorial Advisory Board for Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

MELVILLE, New York-ONI is pleased to announce the creation of an Editorial Advisory Board for Oncology Nursing, to work with Sharon Krumm, PhD, RN, the Editor of Oncology Nursing, and staff to report research by oncology nurses and issues of special interest to oncology nurses. The first two appointees to the board are Catherine (Cathy) Coleman, RN, OCN, and Mary McCabe, BSN, MA.

MELVILLE, New York—ONI is pleased to announce the creation of an Editorial Advisory Board for Oncology Nursing, to work with Sharon Krumm, PhD, RN, the Editor of Oncology Nursing, and staff to report research by oncology nurses and issues of special interest to oncology nurses. The first two appointees to the board are Catherine (Cathy) Coleman, RN, OCN, and Mary McCabe, BSN, MA.

Ms. Coleman is an oncology certified nurse who has dedicated most of her 30-year nursing career to specializing in diseases of the breast and breast center development. She has been a longstanding volunteer for the American Cancer Society and the State of California Department of Health Services, Cancer Detection Section, and has won many awards for outstanding leadership, education, and volunteer services.

Her interests, publications, and passion focus on the complex challenges associated with creating interdisciplinary, research-driven, and patient-focused comprehensive breast centers. As an independent consultant, Ms. Coleman works with community hospitals, academic medical centers, medical device companies, managed care companies, and community-based organizations committed to better breast care.

In 1986, Ms. Coleman was a founding member of the Board of Trustees of the National Consortium of Breast Centers and currently serves on its board.

For the last 6 years, Ms. McCabe has held a number of positions at the National Cancer Institute that have focused on the development of programs and initiatives specific to clinical trials, cancer education, cancer information, and bioethics. From 1996 to 1999, she was assistant director, Division of Cancer Treatment and Diagnosis, and director, Office of Clinical Research Promotion, where she developed a number of initiatives that are components of the NCI’s implementation plan for restructuring its clinical trials program.

Since 1999, Ms. McCabe has served as the director of Education and Special Initiatives; in this role, she has been responsible for reorganizing and expanding the Institute’s education programs. She also works directly with NCI director Andrew von Eschenbach, MD, on institute-wide clinical trials issues and works with the NIH Department of Clinical Bioethics. For more than a year, Ms. McCabe served as acting director of the NCI’s Office of Communications.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content